ABSTRACT
Brain-computer interfaces (BCIs) are systems in which a user's real-time brain activity is used to control an external device, such as a prosthetic limb. BCIs have great potential for restoring lost motor functions in a wide range of patients. However, this futuristic technology raises several ethical questions, especially concerning the degree of agency a BCI affords its user and the extent to which a BCI user ought to be accountable for actions undertaken via the device. This paper examines these and other ethical concerns found at each of the three major parts of the BCI system: the sensor that records neural activity, the decoder that converts raw data into usable signals, and the translator that uses these signals to control the movement of an external device.
ABSTRACT
Cancer is a devastating disease that takes the lives of hundreds of thousands of people every year. Due to disease heterogeneity, standard treatments, such as chemotherapy or radiation, are effective in only a subset of the patient population. Tumors can have different underlying genetic causes and may express different proteins in one patient versus another. This inherent variability of cancer lends itself to the growing field of precision and personalized medicine (PPM). There are many ongoing efforts to acquire PPM data in order to characterize molecular differences between tumors. Some PPM products are already available to link these differences to an effective drug. It is clear that PPM cancer treatments can result in immense patient benefits, and companies and regulatory agencies have begun to recognize this. However, broader changes to the healthcare and insurance systems must be addressed if PPM is to become part of standard cancer care.
